排序方式: 共有93条查询结果,搜索用时 15 毫秒
1.
2.
用改进免疫酶法检测93例治疗前鼻咽癌病人和对照组人群血清的EA/IgA抗体。治疗前病人血清该抗体阳性率为92.4%,平均几何滴度(GMT)1:44.6,而常规法检测阳性率只有75.3%,GMT1:26.9(p<0.01)。对照组中,二种方法检测抗体阳性率无差异。结果表明:改进法测定EA/IgA抗体诊断鼻咽癌更敏感。本文讨论了改进法的优点及重要意义。 相似文献
3.
With gene engineering EB virus membrane antigen as the diagnostic antigen, indirect immunofluo-rescence (IF) assay was used to detect IgA antibody against EB virus membrane antigen (MA-IgA) in sera from 202 nasopharyngeal carcinoma (NPC) patients and 315 controls (normal and patients with other tumors). MA-IgA antibody was positive in 96.8% of the pretreatment NPC patients with a GMT of 1:36.3. MA-IgA detection by this method was more sensitive than EA-IgA detection by IE. In contrast, patients with tumors other than NPC were negative for MA-IgA antibody. 9.1% of VCA-IgA positive persons were MA-IgA positive with a GMT of less than 1:5. No MA-IgA positive was found in VCA-IgA negatives. The results indicated that this method was relatively specific. In the treatment group, the positive rate and GMT of MA-IgA antibody declined with increase in survival time and the decline was faster than VCA-IgA. When recurrence or distant metastasis developed, similar to VCA-IgA and EA-IgA antibodies, the positive rate 相似文献
4.
5.
6.
7.
8.
本文主要探讨治疗前鼻咽癌患者病理类型和免疫功能与血清VCA-IgA抗体的关系。 一、检测对象 1.以检测了血清VCA-IgA抗体水平的1006例治疗前鼻咽癌患者中病理分类明确的819例,作为病理类型与血清VCA-IgA抗体关系的分析对象。 2.测定234例治疗前鼻咽癌患者的免疫功能指标,包括活性T淋巴细胞玫瑰花结形成率(EA-RFC)、T淋巴细胞玫瑰花结形成率(ET-RFC)、归结核菌素(OT)皮试反应(其中208例/234例)、植物血凝 相似文献
9.
10.
本文就作者1964年3月至1979年12月19023例鼻咽癌放疗后随诊中并发其他原发癌49例(50个癌)进行了分析。其他原发癌的出现率为257.6/10万,为同地区正常人群普查癌瘤患病率的两倍。其中,并发的舌癌出现率为63.1/10万,为同地区正常人群普查的舌癌患病率(0.79/10万人口)的80倍,并发其他原发癌在鼻咽癌放疗后2年以上出现者32例(64%)占多数,间胚叶来源的恶性肿瘤出现较迟,多在放疗后5年以上,鼻咽癌放疗后出现头颈部其他癌瘤可能是放射源性的,值得引起注意。 相似文献